SAN.PA - Sanofi
| Previous Close | 71.84 |
| Open | 71.95 |
| Bid | 71.12 x 1000 |
| Ask | 71.74 x 44000 |
| Day's Range | 71.95 - 72.88 |
| 52 Week Range | 62.88 - 86.39 |
| Volume | 2,793,110 |
| Avg. Volume | 2,771,433 |
| Market Cap | 89.785B |
| Beta | 0.78 |
| PE Ratio (TTM) | 24.42 |
| EPS (TTM) | 2.97 |
| Earnings Date | Jul 31, 2018 |
| Forward Dividend & Yield | 3.03 (4.18%) |
| Ex-Dividend Date | 2018-05-11 |
| 1y Target Est | 78.29 |
- GlobeNewswire•6 hours ago
Information concerning the total number of voting rights and shares
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général ...
- GlobeNewswire•2 days ago
Sanofi: Disclosure of trading in own shares
Disclosure of trading in own shares (pdf) This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they ...
- Benzinga•6 days ago
Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 11) AC Immune SA (NASDAQ: ACIU ) Arbutus Biopharma Corp (NASDAQ: ...
- CNW Group•8 days ago
Sanofi denounces CADTH negative recommendation that could limit treatment options for Canadians with atopic dermatitis
LAVAL, QC , July 10, 2018 /CNW Telbec/ - Sanofi Genzyme is disappointed with the recent recommendation by the Canadian Agency for Drugs and Technologies in Health (CADTH) to not reimburse Dupixent™, one of the most important recent pharmacological innovations for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD). This recommendation disregards patient input and ignores the product's clinical value and the potential improvement to patient and caregiver quality-of-life (QoL). In 2017, Health Canada, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved Dupixent™ based on its clinical value and benefits to patients with moderate-to-severe AD.
- Reuters•9 days ago
French government monitoring Sanofi plant at centre of pollution complaint
The French government said on Tuesday that it was monitoring the situation at Sanofi's Mourenx plant in southwestern France to ensure the drugmaker had taken steps against pollution problems before it would allow the plant to re-open. Sanofi said on Monday that it had stopped production at the plant after an environment body filed a complaint against what it said was massive air pollution. France Nature Environnement, a federation representing some 3,500 local associations, said emissions at the Mourenx plant, which produces the epilepsy treatment valproate, had been 7,000 times above the limit allowed by French law.
- GlobeNewswire•9 days ago
Sanofi: Disclosure of trading in own shares
Disclosure of trading in own shares (pdf) This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they ...
- Zacks•9 days ago
Regulus Stock Plunges on Cash Concerns Despite Restructuring
Regulus Therapeutics (RGLS) announces strategic and restructuring plans to extend cash runway. However, investors remain skeptical.
- Motley Fool•12 days ago
Top Stocks Set to Disrupt the Diabetes Market
Revolutionary new drugs and medical devices could make these companies smart additions to your portfolio.
- Market Realist•13 days ago
Some Recent Pharmaceutical Mergers and Acquisitions
The US pharmaceutical sector comprises drug manufacturers, drug marketers, and biotechnology companies. The chart below lists some recent mergers and acquisitions in the sector.
Market Realist•13 days agoSanofi Focuses on Integrating Recently Acquired Ablynx
On January 29, Sanofi announced its acquisition of Ablynx for $4.8 billion, and it announced the completion of the acquisition on June 19. The acquisition was one of two announced in January to advance its blood disorder portfolio. The other acquisition was of Bioverative.
Market Realist•14 days agoUpdates on the Sanofi-Evotec Diabetes Business Collaboration
On June 25, Sanofi and Evotec reached the second milestone of the diabetes business alliance they entered into in August 2015, with a payment of 3 million euros from Sanofi to Evotec after the latter had met “pre-agreed critical success criteria for a potential manufacturing process” for generating human induced pluripotent stem cell-derived beta cells. The deal aims to extend Evotec’s metabolic disease and stem cell-based drug discovery programs and enhance Sanofi’s extensive diabetes research and development pipeline. According to the agreement, Evotec is eligible to receive as much as 300 million euros in milestone-based payments from Sanofi as well as royalties and research payments. To date, the company has received 9 million euros in upfront milestone-based payments and research funding from Sanofi.
Market Realist•14 days agoSanofi Signs Over Anti-Infectives Unit to Evotec
On June 15, Sanofi (SNY) and Evotec, a Germany-based drug discovery and development company, signed an agreement to transfer Sanofi’s anti-infectives unit to Evotec for $70 million. Sanofi will also transfer 100 employees to Evotec and licenses for more than ten infectious disease R&D (research and development) pipeline assets.
Market Realist•14 days agoSanofi Announces Positive Study Results for Toujeo
On June 25, Sanofi (SNY) announced positive results for BRIGHT, a study comparing Sanofi’s Toujeo with Novo Nordisk’s (NVO) Tresiba (degludec). The study results were presented at the American Diabetes Association’s 78th Scientific Sessions in Orlando, Florida.
- Reuters•15 days ago
Sanofi beefs up diabetes pipeline to retrieve success
Sanofi (SASY.PA) sees a more diversified pipeline driving a return to growth at its diabetes unit in the coming years and will consider acquisitions and partnerships to help boost performance, a company executive said on Tuesday. The French drugmaker's diabetes revenues have fallen since 2015, slumping some 11 percent last year alone, as its patent-expired Lantus insulin is being squeezed by pricing pressure in the United States, the world's-largest health market. "I will not commit to a new guidance for 2019 but we are clearly optimistic for the business," Stefan Oelrich, executive vice president for diabetes and cardiovascular at Sanofi, told Reuters.
- Reuters•15 days ago
Sanofi beefs up diabetes pipeline to retrieve success
Sanofi sees a more diversified pipeline driving a return to growth at its diabetes unit in the coming years and will consider acquisitions and partnerships to help boost performance, a company executive said on Tuesday. The French drugmaker's diabetes revenues have fallen since 2015, slumping some 11 percent last year alone, as its patent-expired Lantus insulin is being squeezed by pricing pressure in the United States, the world's-largest health market. "I will not commit to a new guidance for 2019 but we are clearly optimistic for the business," Stefan Oelrich, executive vice president for diabetes and cardiovascular at Sanofi, told Reuters.
Market Realist•15 days agoSanofi’s Partnership with Sensile Medical and Verily
On June 26, Sensile Medical, a Swiss company developing liquid drug-delivery devices, announced that it had entered into a partnership with Sanofi and Verily (formerly Google Life Sciences) for the development and commercialization of a connected insulin patch pump. The below diagram shows Sanofi’s research and development pipeline. In their alliance, the three companies aim to leverage Sensile Medical’s micro-pump technology development leadership, Sanofi’s expertise in insulin and diabetes solutions, and Verily’s experience in micro-electronic integration and digital healthcare technology.
Market Realist•15 days agoAnalyzing Sanofi’s Recent Stock Performance
SNY stock is trading higher than its 50-day moving average of $38.84 and marginally lower than its 200-day moving average of $40.77. Over the last year, Sanofi stock had fallen ~19% as of June 26, while the healthcare industry (XLV) had risen ~5.3%. Peers GlaxoSmithKline (GSK), Pfizer (PFE), and Eli Lilly (LLY) had returned -8.8%, 7.7%, and 2.5%, respectively. In the next article, we’ll discuss Sanofi’s recent partnership with Sensile Medical and Verily in the insulin pump business.
- Market Realist•15 days ago
How Sanofi’s Valuation Compares
Sanofi (SNY) has recently been working on expanding its product portfolio in areas with potential growth and strong margins. As the Sanofi posted weak Q1 2018 performance, mainly triggered by weakness in its diabetes and cardiovascular business, the company has recently entered into a number of collaborations and initiatives to recuperate its business. Let’s look at Sanofi’s valuation metrics as of June 27.
Market Realist•15 days agoAnalysts See a 9.5% Upside for SNY Stock over the Next Year
Sanofi, a global healthcare leader, has a comprehensive product portfolio and pipeline focusing on immunology, oncology, multiple sclerosis, neurology, rare disease disorders, diabetes, cardiovascular diseases, vaccines, and infectious diseases. In Q1 2018, the company’s sales fell and its missed analysts’ estimates. Let’s begin by looking at analysts’ recommendations for SNY stock for the next 12 months.
- Investor's Business Daily•16 days ago
Upside 'Substantial' As Regeneron Ups Price On Blockbuster Hopeful
Regeneron Pharmaceuticals and Sanofi made a first-ever price increase for Dupixent, a potential blockbuster eczema treatment, an analyst said Monday.
- GlobeNewswire•16 days ago
Sanofi: Disclosure of trading in own shares
Disclosure of trading in own shares (PDF) This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they ...
- Zacks•16 days ago
Sanofi's Blood Clotting Drug Gets Positive CHMP Opinion
Sanofi's (SNY) Cablivi for treating acquired thrombotic thrombocytopenic purpura nears approval with CHMP recommendation.
- PR Newswire•16 days ago
Sanofi to further accelerate its scientific presence with the opening of a Global R&D Operations Hub in Chengdu, China
- Company invests €66 million in Chengdu, Sichuan province, China - China is the third pillar of Sanofi Global Clinical Sciences and Operations, developing digitalization and big data analysis CHENGDU, ...
- Zacks•19 days ago
Sanofi (SNY) Finalizes Deal for European Generic Unit Sale
Sanofi (SNY) finalizes sale of its European generic unit, Zentiva, for $2.2 billion.
- GlobeNewswire•20 days ago
Sanofi: Availability of the Pre-quarterly Results Communication
As for each quarter, Sanofi prepared this document to assist in the financial modeling of the Group`s quarterly results. Sanofi`s second-quarter results will be published on July 31, 2018. Sanofi is dedicated to supporting people through their health challenges.
